Literature DB >> 28506571

Tumor necrosis factor receptor-associated factor (TRAF) 6 inhibition mitigates the pro-inflammatory roles and proliferation of rheumatoid arthritis fibroblast-like synoviocytes.

Lang-Jing Zhu1, Tie-Cheng Yang2, Qiang Wu2, Li-Ping Yuan2, Zhen-Wei Chen2, Min-Hong Luo2, Hai-Ou Zeng2, Dong-Ling He2, Cai-Ju Mo2.   

Abstract

BACKGROUND: Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) play a crucial role in RA through producing inflammatory cytokines and proteases which could cause cartilage destruction. We showed previously that elevated expression of tumor necrosis factor receptor-associated factor 6 (TRAF6) in RA synovium correlated significantly with the severity of synovitis and the number of infiltrated inflammatory cells. The aims of this study are to detect the roles of TRAF6 in RA-FLSs.
METHODS: Synovium were collected by closed needle biopsy from inflamed knees of active RA patients, and FLSs were isolated by modified tissue culture method. Expression of TRAF6 and CD55 in RA synivium was tested by double immunofluorescence (IF) staining. TRAF6 in RA-FLSs was inhibited using Lentiviral-TRAF6-shRNA transfection. Real-time PCR and ELISA were used to detect the mRNA expression and secretion of matrix metalloproteinase (MMP) and pro-inflammatory cytokines. Cell Counting Kit-8 was used to detect cell proliferation, flow cytometry was used to detect cell cycle, and Annexin V assay was used to detect cell apoptosis.
RESULTS: We showed that in the intimal and subintimal area of RA synovium, TRAF6 was expressed obviously not only in CD55+ cells, but also in some other CD55- cells. TRAF6 expression in RA-FLSs was suppressed effectively by Lentiviral-TRAF6-shRNA transfection. Inhibition of TRAF6 in RA-FLSs mitigated the mRNA levels and secretion of pro-inflammatory cytokines and MMPs, such as IL-1β, IL-8, IL-6, TNF-α, MMP-13, and MMP-3. In addition, it decreased the proliferation of RA-FLSs, blocked RA-FLSs in G0/G1-phase, and inhibited the cells to go into S-phase and G2/M-phase, but not facilitated apoptosis of RA-FLSs.
CONCLUSION: TRAF6 plays direct roles in the pro-inflammatory effects and proliferation of RA-FLSs. TRAF6 may serve as a potential treatment target in RA.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fibroblast-like synoviocytes; Pro-inflammatory cytokines; Rheumatoid arthritis; Synovitis; Tumor necrosis factor receptor-associated factor (TRAF) 6

Mesh:

Substances:

Year:  2017        PMID: 28506571     DOI: 10.1016/j.cyto.2017.05.001

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  5 in total

1.  TRAF molecules in inflammation and inflammatory diseases.

Authors:  Almin I Lalani; Sining Zhu; Samantha Gokhale; Juan Jin; Ping Xie
Journal:  Curr Pharmacol Rep       Date:  2017-12-20

Review 2.  Structural feature of TRAFs, their related human diseases and therapeutic intervention.

Authors:  Hyun Ho Park
Journal:  Arch Pharm Res       Date:  2021-05-10       Impact factor: 4.946

3.  Delivery of miR-146a to Ly6Chigh Monocytes Inhibits Pathogenic Bone Erosion in Inflammatory Arthritis.

Authors:  Meryem Ammari; Jessy Presumey; Clara Ponsolles; Gautier Roussignol; Christine Roubert; Virginie Escriou; Karine Toupet; Anne-Laure Mausset-Bonnefont; Maïlys Cren; Maxime Robin; Philippe Georgel; Ramzi Nehmar; Leonie Taams; Joachim Grün; Andrea Grützkau; Thomas Häupl; Yves-Marie Pers; Christian Jorgensen; Isabelle Duroux-Richard; Gabriel Courties; Florence Apparailly
Journal:  Theranostics       Date:  2018-11-13       Impact factor: 11.556

Review 4.  Mechanism by which TRAF6 Participates in the Immune Regulation of Autoimmune Diseases and Cancer.

Authors:  Jingjing Wang; Xinjie Wu; Mengyu Jiang; Guixiang Tai
Journal:  Biomed Res Int       Date:  2020-11-26       Impact factor: 3.411

5.  Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis.

Authors:  Ting Li; Yue Li; Jia-Wen Li; Ying-Hui Qin; Hui Zhai; Bin Feng; He Li; Ning-Nannan Zhang; Chun-Sheng Yang
Journal:  BMC Neurol       Date:  2022-08-17       Impact factor: 2.903

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.